Search Results

1 - 7 of 7 items :

  • "haemophilia" x
  • Microbiology and Virology x
Clear All
Global clotting assays - monitoring the effect of by-passing agents in haemophilia patients with inhibitors

. Mancuso ME, Fasulo MR. Thrombin Generation Assay as a Laboratory Monitoring Tool during Bypassing Therapy in Patients with Hemophilia and Inhibitors. Semin Thromb Haemost. 2016;42:30-5. 7. Mancuso ME, Chantaragkul V, Clerici M. Low thrombin generation during major orthopedic surgery fails to predict bleeding risk in inhibitor patients treated with bypassing agents. Haemophilia. 2016;22(4):292-30. DOI: 10.1111/hae.12939 8. Turecek PL, Varadi K, Keil B, Negrier C, Berntorp E, Astermark J, et al. Factor VIII inhibitor-bypassing agents act by

Open access
Prothrombotic risk mutations and polymorphisms in patients with hemophilia A – a preliminary study / Polimorfismele și mutațiile cu risc protrombotic la pacienții cu hemofilie A - studiu preliminar

References 1. van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van den Berg HM. Do prothrombotic factors influence clinical phenotype of severe haemophilia? A review of the literature. Thromb Haemost. 2004 Aug;92(2):305-10. 2. Franchini M, Lippi G. Factor V Leiden and hemophilia. Thromb Res. 2010 Feb;125(2):119-23. DOI: 10.1016/j. thromres.2009.11.003 3. Sanna V, Zarrilli F, Nardiello P, D’Argenio V, Rocino A, Coppola A, et al. Mutational spectrum of F8 gene and prothrombotic gene variants in haemophilia A

Open access
Pitfalls in hemostasis exploration, a case report of a girl with Henoch-Schönlein type vasculitis

References 1. Franchini M, Zaffanello M, Lippi G. Acquired hemophilia in pediatrics: a systematic review.Pediatr Blood Cancer. 2010 Oct; 55(4):606-11. 2. Jan Bain M, Leissinger C, Kruse-Jarres R. Acquired hemophilia A: emerging treatment options. J Blood Med. 2015 May; 6: 143-150. 3. C.Kallanagowdar, A.Chauhan, M.V.Puertolas, R.Warrier. Prevalence and Resolution of Lupus Anticoagulant in Children.Ochsner Journal 2016; 16:172-175. 4. D.Williams, Duncan C. MacIvor.Patient Is Clotting: What Do You

Open access
The influence of hemodialysis on FibroTest parameters

. Petrauskiene V, Vaiciuniene R, Kuzminskis V, Ziginskiene E, Grazulis S, Jonaitiene E, et al. Associations of vascular calcification, calcium phosphate disturbances, FGF 23 and Matrix Gla protein with mortality of hemodialysis patients: one center cohort study. Rev Romana Med Lab. 2018;26(4):451-60. DOI:10.2478/rrlm-2018-0034. DOI: 10.2478/rrlm-2018-0034 49. Maor Y, Calès P, Bashari D, et al. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia. 2007

Open access
Acquired von Willebrand disease: from theory to practice. A single center experience - three case reports

, Nathan DG Eds. Nathan and Oski’s Hematology and Oncology of Infancy and Childhood 8th Ed. Elsevier Saunders, Philadelphia. 2015:1103-24. 23. Tiede A, Priesack J, Werwitzke S, Bohlmann K, Oortwijn B, Lenting P, et al. Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single centre cohort study. J Thromb Haemost. 2008;6(4):569-76. DOI: 10.1111/j.1538-7836.2008.02909.x 24. Manfredi E, van Zaane B, Gerdes V.E.A, Brandjes D.P.M, Squizzato A. Hypothyroidism and acquired von Willebrand’s syndrome: a systematic review. Haemophilia

Open access
What about microparticles? Perspectives and practical aspects

. Tissue factor microparticles and haemophilia. Thromb Res.2010; 125:S67-9 49. Dignat-George F, Feyssinet JM, Key NS. Centrifugation is a crucial step impacting microparticle measurement. Platelets. 2009 ; 20(3):225-6 50. Ayers L, Kohler M, Harrison P, Sargent I, Dragovic R, Schaap M, et al. Measurement of circulating cell-derived microparticles by flow cytometry: Sources of variability within the assay. Thromb Res 2011; 127:370-7 51. Lacroix R, Judicone C, Poncelet P, Robert S, Arnaud L, Sampol J et al. Impact of pre

Open access
Advances in research on influencing factors of hepatitis B virus infection caused by blood transfusions

with cancer, and 2.4% for recipients with hemophilia. In China, local studies also confirmed higher HBV carrier rate of patients with blood diseases than the general population. Among these individuals, the carrier rate reached 31.37% for patients with aplastic anemia, 19.91% for patients with idiopathic thrombocytopenic purpura, and 16.9% for patients with leukemia; the control group of healthy people without blood disease presented a carrier rate of 10.12% [ 18 ]. According to the WHO, nearly 10% of AIDS patients are jointly infected with HBV. Recipients infected

Open access